Loading...
Rational Adaptation of L3MBTL1 Inhibitors to Create Small-Molecule Cbx7 Antagonists.
Simhadri, Chakravarthi Daze, Kevin D Douglas, Sarah F Milosevich, Natalia Monjas, Leticia Dev, Amarjot Brown, Tyler M Hirsch, Anna K H Wulff, Jeremy E Hof, Fraser
Simhadri, Chakravarthi
Daze, Kevin D
Douglas, Sarah F
Milosevich, Natalia
Monjas, Leticia
Dev, Amarjot
Brown, Tyler M
Hirsch, Anna K H
Wulff, Jeremy E
Hof, Fraser
Citations
Altmetric:
Advisors
Editors
Other Contributors
Issue Date
2019-08-06
Submitted date
Files
Loading...
submitted manuscript
Adobe PDF, 3.04 MB
Other Titles
Abstract
Chromobox homolog 7 (Cbx7) is an epigenetic modulator that is an important driver of multiple cancers. It is a methyl reader protein that operates by recognizing and binding to methylated lysine residues on specific partners. Herein we report our efforts to create low-molecular-weight inhibitors of Cbx7 by making rational structural adaptations to inhibitors of a different methyl reader protein, L3MBTL1, inhibitors that had previously been reported to be inactive against Cbx7. We evaluated each new inhibitor for Cbx7 inhibition by fluorescence polarization assay, and also confirmed the binding of selected inhibitors to Cbx7 by saturation-transfer difference NMR spectroscopy. This work identified multiple small-molecule inhibitors with modest (IC50 : 257-500 μm) potency.
Citation
ChemMedChem. 2019 Aug 6;14(15):1444-1456. doi: 10.1002/cmdc.201900021. Epub 2019
Publisher
Journal
PubMed ID
PubMed Central ID
Additional Links
Embedded video
Type
Article
Language
en
Description
Series/Report no.
ISSN
1860-7187
EISSN
ISBN
ISMN
Gov't Doc #
Sponsors
License
Attribution-NonCommercial-ShareAlike 4.0 International